retatrutide clinical trial benefits Perceived of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 Retatrutide: What It Is &

Both compounds have been studied in mixed-gender populations

Before considering any GLP-1 or related weight-management therapy, discuss eligibility, risks, and approved alternatives with a licensed clinician

Gastrointestinal disturbances, which were mostly mild to moderate, occurred more frequently with oral SMG 25 mg and 50 mg than with the 14 mg dose, but without raising concerns about potential safety risks

Analysis based on information available as of December 26, 2025

Artola, el envejecimiento de la poblacin y la escalada de la obesidad son factores que estn haciendo aumentar exponencialmente el nmero de personas con diabetes tipo 2

We can now confidently say we have a drug that matches bariatric surgery outcomes